Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898515 | 0.85 | ALDH1A1 (0.62) | ALDH1A1 | |
| Pentrinitrol SCHEMBL122322 | 0.76 | ALDH1A1 (0.71) | ALDH1A1LMNA | |
| Pentaerythrityl Mononitrate SCHEMBL2293171 | 0.76 | ALDH1A1 (0.71) | ALDH1A1LMNA | |
| Pentaerythrityl Dinitrate SCHEMBL2290461 | 0.76 | ALDH1A1 (0.71) | ALDH1A1LMNA | |
| Pentrinitrol SCHEMBL15777772 | 0.76 | ALDH1A1 (0.71) | ALDH1A1LMNA | |
| SCHEMBL6360345 | 0.75 | ALDH1A1 (0.62) | ALDH1A1 | |
| SCHEMBL1730047 | 0.75 | — | — | |
| Pentrinitrol SCHEMBL3884946 | 0.74 | ALDH1A1 (0.68) | ALDH1A1LMNA | |
| SCHEMBL4649499 | 0.73 | ALDH1A1 (0.52) | ALDH1A1LMNA | |
| SCHEMBL10720457 | 0.73 | ALDH1A1 (0.52) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1673384-A4 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1673384-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030135-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | GLS, NOS2, NOS1 | ALDH1A1 883/4885LMNA 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.